Kinetics of Microbial Translocation Markers in Patients on Efavirenz or Lopinavir/R Based Antiretroviral Therapy

PLoS ONE - United States
doi 10.1371/journal.pone.0055038
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Public Library of Science (PLoS)

Related search

Random Lopinavir Concentrations Predict Resistance on Lopinavir-Based Antiretroviral Therapy

International Journal of Antimicrobial Agents
MedicineInfectious DiseasesMicrobiologyPharmacology
2016English

Relationship Between Plasma Bilirubin Level and Oxidative Stress Markers in HIV-infected Patients on Atazanavir-Vs. Efavirenz-Based Antiretroviral Therapy

HIV Medicine
Health PolicyInfectious DiseasesPharmacology
2016English

Efficacy and Tolerability of Lopinavir/Ritonavir- And Efavirenz-Based Initial Antiretroviral Therapy in HIV-1-Infected Patients in a Tertiary Care Hospital in Beijing, China

Frontiers in Pharmacology
Pharmacology
2019English

Metabolic Abnormalities and Body Composition of HIV-infected Children on Lopinavir or Nevirapine-Based Antiretroviral Therapy

Archives of Disease in Childhood
Child HealthPediatricsPerinatology
2012English

‘Covering the Tail’ After Stopping Efavirenz-Based Antiretroviral Therapy

Southern African Journal of HIV Medicine
Infectious Diseases
2020English

Serological Markers for Inflammatory Bowel Disease in AIDS Patients With Evidence of Microbial Translocation

PLoS ONE
Multidisciplinary
2010English

Lack of Effect From a Previous Single Dose of Nevirapine on Virologic and Immunologic Responses After 6 Months of Antiretroviral Regimens Containing Either Efavirenz or Lopinavir-Ritonavir

Pharmacotherapy
Pharmacology
2011English

The Frequency of Malaria Is Similar Among Women Receiving Either Lopinavir/Ritonavir or Nevirapine-Based Antiretroviral Treatment

PLoS ONE
Multidisciplinary
2012English

New Insight of Antiretroviral Drug Efavirenz as Anticancer Agents for Breast Cancer Therapy

Cancer Cell & Microenvironment
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy